1Fishbane S. What is needed to achieve a hemoglobin of 11.0-13. 0 g/dl in End stage renal disease[J]. Blood Pruif, 2007, 25:53-57.
2Portoles J, Lopez- Gomez JM, Aljama P. On behalf of the MAR Study Group. A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study[J]. Nephrol Dial Transplant, 2007, 22:500-507.
3Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)[J]. Nephrol Dial Transplant, 2004,19:121-132.
4Tarng DC, Huang TP, Chen TW, et al. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload[J]. Kidney Int, 1999, 69( Supp 1): 107-118.
5Fudin R, Jaichenko J, Shostak A, et al. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study[J]. Nephron, 1998, 79 (3) : 299-305.
6Macdougall IC, Tucker B, Thomp son J, et al. A randomized controlled study of iron supp lementation in patients treated with erythropoietin[J]. Kidney Int, 1996,50 (5): 1694 - 1699.
4Portoles J,Lopez-Gomez JM,Aljama P.On behalf of the MAR Study Group.A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients:the MAR Study.Neohrol Dial Transplant,2007,22:500-507.
5Lecatelli F,Pisoni RL,Combe C,et al.Anaemia in haemodialysis patients of five European countries:association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).Nephrol Dial Transplant,2004,19:121-132.
6Vanwyck DB,Danielson BG,Aronoff GR.Making sense:A scientific approach to intravenous iron therapy.J Am Soc Nephrol,2004,15:91-92.
7Danielson BG.Structure,chemistry,and pharmaeokineties of intravenous iron agents.J Am Soc Nephrol,2004,15:93-98.
8Aronoff GR.Safety of intravenous iron in clinical practice:implications for anemia management protocols.J Am Soc Nephrol,2004,15:99-106.
9VanWyck DB.Labile iron:manifestations and clinical implications.J Am Soc Nephrol,2004,15:107-111.
10Fishbane S. What is needed to achieve a hemoglobin of 11.0 - 13.0 g/dl in end-stage renal disease. Blood Pruif,2007 ,25 :53 -57.
4Fishbane S. What is needed to achieve a hemoglobin of 11.0 - 13.0 g/dl in End stage renal disease [ J]. Blood Pruif,2007,25 ( 1 ) :53 - 57.
5Fudin R, Jaichenko J, Shostak A, et al. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study [J]. Nephron, 1998,79 ( 3 ) :299 - 305.
6von Haehling S,van Veldhuisen DJ,Roughton M. Anaemia among patients with heartfailure and preseerved or reduced ejection fraction:results from the SENIORS study[J].European Journal of heart failure,2011,(6):656-663.
7Groenveld HF,Januzzi JL,Damman K. Anemia and mortality in heartfailure patients a systematic review and meta-analysis[J].Journal of the America College of Cardiology,2008,(10):818-827.
8中华医学会.临床诊疗指南-心血管内科分册[M]北京:人民卫生出版社,200911-25.
9van der Meer P,van Veldhuizen DJ. Anaemia and renal dysfunction in chronic heart failure[J].HEART,2009.1808-1812.
10Davila C,Reyentovich A,Katz SD. Clinical correlates of hemoconcentration during hospitalization for acute decompensated heart failure[J].Journal of Cardiac failure,2011,(12):1018-1022.
